Company intelligence / Profile preview
Spur Therapeutics
Stevenage, United Kingdomspurtherapeutics.com ↗
- Ownership
- Private
- Employees
- ~50
- Development stage
- Phase 2
01
Overview
Positive data from Phase 1/2 GALILEO-1 trial of FLT201 for Gaucher disease; completed enrollment for Phase 1/2 trial with Phase 3 planned for 2025; ongoing Phase 1/2 PROPEL study for SBT101 with initial safety data expected in first half of 2025
- Therapeutic areas
- CardiovascularRare DiseasesNeurology
- Modalities
- Gene therapyAAV (adeno-associated virus) gene therapy
- Industry
- Biotech
02
Drug pipeline
8 assets7 more assets in the full pipeline.
Beyond the preview
Go deeper on Spur Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Spur Therapeutics.